BACKGROUND AND PURPOSE: Rapid and safe recanalization of occluded intracranial arteries in acute ischemic stroke (AIS) is challenging. Newly available self-expanding intracranial atherosclerotic stents (SEIS), which can be deployed rapidly and safely, make acute stenting an option for treating AIS. We present the feasibility of this technique. METHODS: A retrospective analysis evaluated procedural protocols and clinical response to treatment in patients with AIS treated with SEIS. Descriptive statistics are presented with initial and follow-up National Institutes of Health Stroke Scale and modified Rankin Score. RESULTS: Nine patients with AIS underwent acute SEIS placement. There was successful deployment of the Neuroform (n=4) and Wingspan (n=4/5) stents in the M1/M2 (n=5) and M3 (n=1) middle cerebral artery segments, intracranial internal carotid artery (one of 2), and intracranial vertebrobasilar junction (one). Mean time of SEIS deployment from AIS onset was 5.1 hours. Complete (Thrombolysis in Cerebral Ischemia/Thrombolysis in Myocardial Ischemia 3) and partial/complete (Thrombolysis in Cerebral Ischemia/Thrombolysis in Myocardial Ischemia 2 or 3) recanalization occurred in 67% and 89%, respectively. One intracranial hemorrhage (11%) and one acute in-stent thrombosis (successfully treated with abciximab and balloon angioplasty) occurred. Stroke-related mortality occurred in 3 of 9 (33%) patients and survivors had modified Rankin Score < or = 2. Follow-up angiography (mean, 8 months; range, 2 to 14 months) in 4 of 9 patients showed no stent restenosis. CONCLUSIONS: This preliminary experience with SEIS in refractory AIS demonstrated the technical feasibility and high rate of recanalization with acute stenting. Long-term safety and strategies to limit in-stent thrombosis and optimize periprocedural management are crucial before initiating future randomized efficacy studies with SEIS in AIS refractory to standard therapy.
BACKGROUND AND PURPOSE: Rapid and safe recanalization of occluded intracranial arteries in acute ischemic stroke (AIS) is challenging. Newly available self-expanding intracranial atherosclerotic stents (SEIS), which can be deployed rapidly and safely, make acute stenting an option for treating AIS. We present the feasibility of this technique. METHODS: A retrospective analysis evaluated procedural protocols and clinical response to treatment in patients with AIS treated with SEIS. Descriptive statistics are presented with initial and follow-up National Institutes of Health Stroke Scale and modified Rankin Score. RESULTS: Nine patients with AIS underwent acute SEIS placement. There was successful deployment of the Neuroform (n=4) and Wingspan (n=4/5) stents in the M1/M2 (n=5) and M3 (n=1) middle cerebral artery segments, intracranial internal carotid artery (one of 2), and intracranial vertebrobasilar junction (one). Mean time of SEIS deployment from AIS onset was 5.1 hours. Complete (Thrombolysis in Cerebral Ischemia/Thrombolysis in Myocardial Ischemia 3) and partial/complete (Thrombolysis in Cerebral Ischemia/Thrombolysis in Myocardial Ischemia 2 or 3) recanalization occurred in 67% and 89%, respectively. One intracranial hemorrhage (11%) and one acute in-stent thrombosis (successfully treated with abciximab and balloon angioplasty) occurred. Stroke-related mortality occurred in 3 of 9 (33%) patients and survivors had modified Rankin Score < or = 2. Follow-up angiography (mean, 8 months; range, 2 to 14 months) in 4 of 9 patients showed no stent restenosis. CONCLUSIONS: This preliminary experience with SEIS in refractory AIS demonstrated the technical feasibility and high rate of recanalization with acute stenting. Long-term safety and strategies to limit in-stent thrombosis and optimize periprocedural management are crucial before initiating future randomized efficacy studies with SEIS in AIS refractory to standard therapy.
Authors: J S Bang; C W Oh; C Jung; S Q Park; K J Hwang; H-S Kang; M H Han; S H Lee; Y S Chung; O-K Kwon Journal: AJNR Am J Neuroradiol Date: 2010-04-01 Impact factor: 3.825
Authors: P Mordasini; N Frabetti; J Gralla; G Schroth; U Fischer; M Arnold; C Brekenfeld Journal: AJNR Am J Neuroradiol Date: 2010-10-21 Impact factor: 3.825
Authors: Marc A Lazzaro; Roberta L Novakovic; Andrei V Alexandrov; Ziad Darkhabani; Randall C Edgell; Joey English; Donald Frei; Dara G Jamieson; Vallabh Janardhan; Nazli Janjua; Rashid M Janjua; Irene Katzan; Pooja Khatri; Jawad F Kirmani; David S Liebeskind; Italo Linfante; Thanh N Nguyen; Jeffrey L Saver; Lori Shutter; Andrew Xavier; Dileep Yavagal; Osama O Zaidat Journal: Neurology Date: 2012-09-25 Impact factor: 9.910
Authors: C Brekenfeld; G Schroth; P Mordasini; U Fischer; M-L Mono; A Weck; M Arnold; M El-Koussy; J Gralla Journal: AJNR Am J Neuroradiol Date: 2011-05-12 Impact factor: 3.825
Authors: Susan T Laing; Melanie R Moody; Hyunggun Kim; Beverly Smulevitz; Shao-Ling Huang; Christy K Holland; David D McPherson; Melvin E Klegerman Journal: Thromb Res Date: 2011-11-30 Impact factor: 3.944